Equities analysts predict that Celgene Co. (NASDAQ:CELG) will report earnings of $2.31 per share for the current quarter, according to Zacks. Eight analysts have issued estimates for Celgene’s earnings, with the highest EPS estimate coming in at $2.36 and the lowest estimate coming in at $2.26. Celgene reported earnings per share of $2.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 15.5%. The company is scheduled to report its next earnings results on Thursday, January 24th.

According to Zacks, analysts expect that Celgene will report full year earnings of $8.80 per share for the current financial year, with EPS estimates ranging from $8.75 to $8.84. For the next year, analysts expect that the company will post earnings of $10.48 per share, with EPS estimates ranging from $9.93 to $11.21. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Celgene.

Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.02 by $0.27. The firm had revenue of $3.89 billion for the quarter, compared to analysts’ expectations of $3.83 billion. Celgene had a net margin of 19.64% and a return on equity of 108.76%.

CELG has been the topic of a number of analyst reports. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Celgene in a research report on Thursday, October 25th. BidaskClub upgraded shares of Celgene from a “hold” rating to a “buy” rating in a research report on Thursday, August 16th. Mizuho reiterated a “buy” rating and issued a $129.00 target price on shares of Celgene in a research report on Tuesday, July 31st. UBS Group set a $94.00 target price on shares of Celgene and gave the stock a “buy” rating in a research report on Saturday, October 27th. Finally, Morgan Stanley lifted their target price on shares of Celgene from $91.00 to $93.00 and gave the stock an “equal weight” rating in a research report on Friday, July 27th. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Celgene has an average rating of “Buy” and a consensus target price of $117.91.

Shares of NASDAQ:CELG opened at $70.24 on Friday. The firm has a market capitalization of $49.66 billion, a P/E ratio of 10.27, a price-to-earnings-growth ratio of 0.44 and a beta of 1.53. Celgene has a 52 week low of $70.09 and a 52 week high of $110.81. The company has a debt-to-equity ratio of 4.06, a quick ratio of 1.99 and a current ratio of 2.13.

A number of institutional investors have recently made changes to their positions in CELG. Ayalon Holdings Ltd. bought a new stake in shares of Celgene during the 2nd quarter valued at about $100,000. Atlantic Trust LLC bought a new stake in shares of Celgene during the 2nd quarter valued at about $101,000. Harvest Fund Management Co. Ltd bought a new stake in shares of Celgene during the 3rd quarter valued at about $132,000. City Holding Co. bought a new stake in shares of Celgene during the 2nd quarter valued at about $143,000. Finally, Sun Life Financial INC boosted its stake in shares of Celgene by 528.9% during the 2nd quarter. Sun Life Financial INC now owns 1,918 shares of the biopharmaceutical company’s stock valued at $152,000 after purchasing an additional 1,613 shares in the last quarter. 73.72% of the stock is currently owned by institutional investors and hedge funds.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Story: The Discount Rate – What You Need to Know

Get a free copy of the Zacks research report on Celgene (CELG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.